• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » Addiction Treatment

Addiction Treatment
Addiction Treatment RSS Feed RSS

Clinical Update

Effective Management of Buprenorphine-Precipitated Opioid Withdrawal

January 1, 2025
Jaewon Lee, MD, MPH
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Jaewon Lee, MD, MPH. PGY-2, psychiatry resident, University of Rochester Medical Center, Rochester, NY. 

Dr. Lee has no financial relationships with companies related to this material.

Buprenorphine is a first-line treatment for opioid use disorder, however, given buprenorphine to a patient who still has opioids in their system can precipitate severe withdrawal. Careful assessment of withdrawal can minimize the risk, but despite our best efforts, precipitated withdrawal can still occur. In this article, we review what to do for our patients experiencing buprenorphine-precipitated opioid withdrawal.


Read More
Clinical Update

Boost or Bust: Navigating the Risks of Prescription Stimulants

October 1, 2024
David Stiffler, MD and Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

David Stiffler, MD. Clinical Associate Professor of Psychiatry and Medical Director of the Steven A. Cohen Military Family Center at NYU Grossman School of Medicine, New York, NY.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Stiffler and Capurso have no financial relationships with companies related to this material.

Prescription stimulants, while effective for treating ADHD, are widely taken without a prescription, particularly by young adults for cognitive enhancement, weight loss, and recreational purposes. This misuse poses serious risks, from developing stimulant use disorder to experiencing severe cardiovascular and psychiatric effects. In this article, you'll learn about the prevalence and patterns of stimulant misuse, its associated dangers, and tips on how to manage it in clinical practice.


Read More

Erratum

October 1, 2024
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue
Research Update

How Do We Help Depressed Smokers Quit?

October 1, 2024
Justin Morales, MD and Deepti Anbarasan, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Justin Morales, MD, and Deepti Anbarasan, MD. Drs. Morales and Anbarasan have no financial relationships with companies related to this material.

Tobacco smoking and major depression are highly comorbid, and depressed patients usually have a tougher time quitting than their non-depressed counterparts. In this research study, investigators compared the efficacy of anti-smoking medications in those with depression. The results may surprise you.


Read More
Expert Q&A

Contingency Management for Stimulant Use Disorder

October 1, 2024
Dominick DePhilippis, PhD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

QA2_DePhilippis Headshot.jpgDominick DePhilippis, PhD 

Deputy National Mental Health Director, Substance Use Disorders, Office of Mental Health, Veterans Health Administration, Department of Veterans Affairs.

Dr. DePhilippis has no financial relationships with companies related to this material.

Contingency management (CM) is a clinical approach that leverages principles of operant conditioning to treat stimulant use disorder. In this interview, Dr. DePhilippis explains how CM incentivizes recovery behaviors like abstinence with immediate rewards, making it an effective treatment tool. Learn how this evidence-based strategy works, why it’s considered the gold standard for treating stimulant use disorder, and the challenges of implementing CM in real-world settings.


Read More
Expert Q&A

Update on Stimulant Use Disorder

October 1, 2024
Brian Hurley, MD, MBA, FAPA, DFASAM
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

QA1_Hurley_Headshot.jpgBrian Hurley, MD, MBA, FAPA, DFASAM 

Addiction physician; President of the American Society for Addiction Medicine; Medical Director of the Bureau of Substance Abuse Prevention and Control, Los Angeles County Department of Public Health, Los Angeles, CA.

Dr. Hurley has no financial relationships with companies related to this material.

The interview with Dr. Hurley provides crucial insights into the world of psychostimulants, their misuse, and the emerging Fourth Wave of the Overdose Epidemic. Dr. Hurley discusses everything from the differences between stimulants like methamphetamine and cocaine to the importance of harm reduction strategies and evidence-based treatments for stimulant use disorder.


Read More
E57FF121-5998-4A2D-A5EB-B87A55EEAF55.png
Clinical Update

Overview of Stimulants

October 1, 2024
Michael Weaver, MD, FASAM and Noah Capurso, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Associate Professor of Psychiatry, Yale University, and Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

This article offers an insightful overview of the pharmacology of various stimulant drugs, their potential for misuse, and the dangers they pose—especially with rising overdose rates due to contamination with fentanyl. Learn about the history, various classes of stimulants, and the treatments available for stimulant use disorder, as well as the crucial harm reduction strategies aimed at minimizing risks.


Read More

CME Post-Test, Stimulants, CATR, October/November/December 2024

October 1, 2024
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

By successfully completing the test you will be awarded a certificate for 2 CME credit.


Read More

Learning Objectives, Stimulants, CATR, October/November/December 2024

October 1, 2024
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

After reading these articles, you should be able to…


Read More
Research Update

Daily Alcohol Intake and Risk for All-Cause Mortality

July 1, 2024
Eli Neustadter, MD, MSc.
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Eli Neustadter, MD, MSc. Dr. Neustadter has no financial relationships with companies related to this material.

It was once thought that moderate alcohol intake was protective against cardiovascular disease. However, new research has revealed flaws in the methodology of these old studies and instead finds that even in moderation, alcohol does not have health benefits and can increase mortality at lower doses than once thought, particularly for women.


Read More
Previous 1 2 3 4 5 6 7 8 9 … 49 50 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • OUDFB1e_Cover_Binding.png

    Treating Opioid Use Disorder—A Fact Book (2024)

    All the tools you need to assess and treat patients struggling with opioid use disorder. 
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2639254965.jpg
    General Psychiatry

    Psychopharm Secrets: Starting Meds

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.